Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

Autor: Joan Morote, Emilio Esteban, L A San José, Miriam Mendez, C de la Piedra, A García-Escudero, A Murias, Cristina Meseguer, M. Unda, B González-Gragera, C González-Enguita, M Constela, E. Solsona, Comet-Batlle J, A G del Alba, J M Martínez-Javaloyas, A Lassa, J.M. Fernandez, Gustavo Rubio, E. Sánchez, Antonio Alcaraz, Ana Mañas, P Samper, Angel Tabernero, Maria J. Ribal, V Calderero, C Quicios, Juan Antonio Virizuela, Marta Martín-Fernández, Joaquim Bellmunt, Urbano Anido, Antonio Gómez-Caamaño, J A Contreras, Ignacio Mahillo-Fernández, Gaspar Reynés, Joan Carles, J Segarra, Daniel U. Campos Delgado, Federico Vazquez, F Gómez-Veiga, P C Lara, Bárbara Rodríguez, Jose Luis Alvarez-Ossorio
Přispěvatelé: UAM. Departamento de Cirugía
Rok vydání: 2013
Předmět:
Male
Oncology
Cancer Research
humanos
estudios de seguimiento
Zoledronic Acid
Bone remodeling
Prostate cancer
bone metastases
Risk Factors
Overall survival
mediana edad
Aged
80 and over
anciano
Bone Density Conservation Agents
Diphosphonates
Imidazoles
análisis de supervivencia
Middle Aged
Prognosis
prostate cancer
pronóstico
Predictive value of tests
Bone Remodeling
Skeletal-related events
medicine.drug
medicine.medical_specialty
Medicina
overall survival
Bone Neoplasms
conservadores de la densidad ósea
bone markers
disease progression
N-terminal telopeptide
progresión de la enfermedad
Predictive Value of Tests
Internal medicine
medicine
factores de riesgo
Humans
difosfonatos
Molecular Diagnostics
Survival analysis
neoplasias óseas
Aged
pruebas de valores predictivos
Disease progression
business.industry
Proportional hazards model
Bone metastases
Prostatic Neoplasms
medicine.disease
Survival Analysis
skeletal-related events
Surgery
Zoledronic acid
remodelación ósea
neoplasias de la próstata
business
Biomarkers
Follow-Up Studies
Zdroj: BRITISH JOURNAL OF CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
British Journal of Cancer
Biblos-e Archivo. Repositorio Institucional de la UAM
ISSN: 1532-1827
0007-0920
DOI: 10.1038/bjc.2013.270
Popis: Background: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk, disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA). Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients were treated with ZA (4mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after the beginning of treatment. Serum levels of bone alkaline phosphtase (BALP), aminoterminal propeptide of procollagen type I (P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (beta-CTX) were analysed at all points in the study. Data on disease progression, SREs development and survival were recorded. Results: Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were predictive of survival time, with beta-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship between bone markers and disease progression. Conclusion: In patients with PCa and bone metastases treated with ZA, beta-CTX and P1NP can be considered suitable predictors for mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of treatment are especially important.
This study was supported by Novartis Oncology Spain. As this was a multicenter study, Adknoma Health Research (Barcelona, Spain) collected and ordered data throughout the study. We especially thank Margarida Garcia from Adknoma who followed carefully the development of the study. M. Martin-Fernandez was a fellow of the Conchita Rabago Foundation.
Databáze: OpenAIRE
Externí odkaz: